PRLD
Prelude Therapeutics Inc
$3.84
+0.79%
$305.8M
No data for this timeframe.
Vol
Market Cap$305.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders6 funds
Inst. Value$8.2M
Inst. Activity2 buys / 2 sells
Insider Activity3B / 0S
Insider Net $$15.5M
Reddit Sentiment67° Warm
SEC Reports6
Press Releases2
Recent Activity
May 12, 2026
SEC
Prelude Therapeutics reported Q1 2026 results with a net loss of $0.13 per share, significantly narrower than the $0.42
8-K — Impact 6/10
May 12, 2026
SEC
Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensu
PRESS-RELEASE — Impact 7/10
May 12, 2026
earnings
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F
May 1, 2026
Insider
Morris Charles Q sold 450,000 shares
Chief Medical Officer @ $4.70 ($2.1M)
Apr 28, 2026
SEC
Three major insiders (OrbiMed Advisors, Baker Bros. Advisors, and David P. Bonita) purchased a combined $15.51M of PRLD
CLUSTER — Impact 8/10
Apr 27, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. sold 1,407,000 shares
10%+ Owner @ $0.00 ($0.00)
Apr 27, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. sold 1,407,000 shares
10%+ Owner @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
1,413,986 shares ($4.1M)
Price Targets
$8.00
+103.0% upside
Strong Buy
Current $3.94
Low $6.00
Median $8.00
High $10.00
3 analysts
$6.00
$10.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | D. Boral Capital | INITIATE | Buy |
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +4.6% | $-0.30 — $-0.20 | 41% YoY | 3 |
| Next Q | $-0.24 ▲ +4.0% | $-0.32 — $-0.18 | 8% YoY | 3 |
| Current FY | $-0.95 ▲ +6.9% | $-1.23 — $-0.69 | 26% YoY | 3 |
| Next FY | $-0.94 | $-1.02 — $-0.86 | 1% YoY | 2 |
Latest Reports
BULLISH
8-K
6/10
Prelude Therapeutics reported Q1 2026 results with a net loss of $0.13 per share, significantly narrower than the $0.42
May 12, 2026
BULLISH
PRESS-RELEASE
7/10
Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensu
May 12, 2026
BULLISH
Press
7/10
Prelude Therapeutics announced positive preclinical data for its lead candidate PRT13722, a first-in-class, selective KA
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $2.3M | DOUBLED |
| MORGAN STANLEY | $971.3K | — |
| RENAISSANCE TECHNOLOGIES LLC | $786.8K | TRIM |
| BANK OF AMERICA CORP | $28.4K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | Morris Charles | A | $2.1M |
| Apr 27, 2026 | RA CAPITAL | J | $0.00 |
| Apr 27, 2026 | RA CAPITAL | J | $0.00 |
| Apr 21, 2026 | ORBIMED ADVISORS | BUY | $7.5M |
| Apr 21, 2026 | Bonita David | BUY | $7.5M |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
6 institutional holders with $8.2M total value (2,824,857 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,413,986 | $4.1M | 50.1% | ADD +42.4% |
| 2 | TWO SIGMA INVESTMENTS, LP | 788,695 | $2.3M | 27.9% | DOUBLED +418.1% |
| 3 | MORGAN STANLEY | 334,916 | $971.3K | 11.9% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 271,300 | $786.8K | 9.6% | TRIM -50.1% |
| 5 | BANK OF AMERICA CORP /DE/ | 9,808 | $28.4K | 0.3% | TRIM -26.9% |
| 6 | FMR LLC | 6,152 | $17.8K | 0.2% | TRIM -32.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 992,854 | 1,413,986 | +42.4% | $4.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 152,233 | 788,695 | +418.1% | $2.3M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 544,000 | 271,300 | -50.1% | $786.8K | 2025-Q4 |
| FMR LLC | TRIM | 9,099 | 6,152 | -32.4% | $17.8K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 104,204 | 4,171 | -96.0% | $6.0K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 80,845 | 0 | -100.0% | $0.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 114,050 | 80,845 | -29.1% | $65.4K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 15,446 | 11,293 | -26.9% | $9.1K | 2025-Q2 |
| FMR LLC | TRIM | 20,238 | 11,167 | -44.8% | $9.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 7,912 | 297 | -96.2% | $240.00 | 2025-Q2 |
| UBS Group AG | ADD | 67,390 | 96,156 | +42.7% | $73.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 16,697 | 23,934 | +43.3% | $18.4K | 2025-Q1 |
| FMR LLC | DOUBLED | 8,502 | 20,238 | +138.0% | $15.5K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 196,900 | 634,500 | +222.2% | $809.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 7,016 | 67,390 | +860.5% | $85.9K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 6,053 | 7,737 | +27.8% | $9.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 133,249 | — | $275.8K | 2024-Q3 |
9 unique insiders with 3 transactions. Net insider value: $15.5M ($15.5M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | Morris Charles Q | Chief Medical Officer | A | 450,000 | $4.70 | $2.1M |
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | J | 1,407,000 | $0.00 | $0.00 |
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | J | 1,407,000 | $0.00 | $0.00 |
| Apr 21, 2026 | ORBIMED ADVISORS LLC | Director | BUY | 1,689,189 | $4.44 | $7.5M |
| Apr 21, 2026 | Bonita David P | Director | BUY | 1,689,189 | $4.44 | $7.5M |
| Apr 21, 2026 | BAKER BROS. ADVISORS LP | Director | BUY | 114,601 | $4.44 | $508.8K |
| Feb 4, 2026 | Combs Andrew | Chief Chemistry Officer | A | 230,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Vaddi Krishna | CEO | A | 837,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Scherle Peggy | Chief Scientific Officer | A | 230,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Lim Bryant David | CLO, CFO, Corp Sec. | A | 275,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.2/10.
BULLISH
8-K
6/10
Prelude Therapeutics reported Q1 2026 results with a net loss of $0.13 per share, significantly narr
May 12, 2026
BULLISH
PRESS-RELEASE
7/10
Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4
May 12, 2026
BULLISH
CLUSTER
8/10
Three major insiders (OrbiMed Advisors, Baker Bros. Advisors, and David P. Bonita) purchased a combi
Apr 28, 2026
BULLISH
3
6/10
RA Capital Healthcare Fund LP and related entities filed Form 3 initial beneficial ownership, disclo
Apr 28, 2026
BULLISH
8-K
7/10
Prelude Therapeutics presented positive preclinical data for its lead drug candidate PRT13722, a fir
Apr 20, 2026
NEUTRAL
8-K
3/10
Prelude Therapeutics appointed Dr. Charles Morris as Chief Medical Officer effective April 20, 2026.
Apr 15, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.00 mean target
+103.0% upside
Strong Buy (1.33)
$6.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $3.94 |
| Target Low | $6.00 |
| Target Mean | $8.00 |
| Target Median | $8.00 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.30 | $-0.20 | 40.6% | +4.6% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.24 | $-0.32 | $-0.18 | 7.7% | +4.0% | 1↑ 0↓ | $0.0B | 412.8% | 3 |
| Current FY 2026-12-31 |
$-0.95 | $-1.23 | $-0.69 | 26.4% | +6.9% | 1↑ 0↓ | $0.0B | 212.4% | 3 |
| Next FY 2027-12-31 |
$-0.94 | $-1.02 | $-0.86 | 1.1% | — | 1↑ 0↓ | $0.1B | 40.6% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.243 | |
| 7d ago | $-0.230 | -0.013 |
| 30d ago | $-0.255 | +0.012 |
| 60d ago | $-0.280 | +0.037 |
| 90d ago | $-0.285 | +0.042 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | D. Boral Capital | INITIATE | — | Buy |
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Biggest insider buys this week
▲ 1
💬 0
⚡ 0.5
May 12, 2026
earnings
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV)
May 12, 2026
earnings_calendar
PRLD Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
PRLD Q1 2026 Earnings Scheduled — 2026-05-11
May 4, 2026
earnings_calendar
PRLD Q1 2026 Earnings Scheduled — 2026-05-04
Apr 21, 2026
short_interest
FTD: PRLD — 393,976 shares ($1.8M) failed to deliver
Settlement: 20260421, Price: $4.51, FTD Value: $1,776,831.76, PRELUDE THERAPEUTICS INC
Apr 20, 2026
other
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
<p align="left">WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”),
Apr 20, 2026
fda
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
<p align="center"><em>Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multip
Apr 15, 2026
other
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
<p>WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”),
Mar 18, 2026
earnings_calendar
PRLD Q4 2025 Earnings After Market Close — 2026-03-18
Mar 17, 2026
routine
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
<p>WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announ
Mar 10, 2026
earnings
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
<p align="center"><em>Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the f
Mar 9, 2026
earnings_calendar
PRLD Q4 2025 Earnings After Market Close — 2026-03-09